Skip to content
Header links
CN
US
INT
linkedin
H. pylori
Point of care testing
Batch testing for labs
BreathID® for pediatrics
Recommended Guidelines
Clinical Positions
Reimbursement Positions
H. pylori Resource
Liver
NASH
CSPH
ALF
Corporate
Quick Facts
Financial reports
Events
Management team
Board of directors
Scientific advisory board
Resources
H. pylori
Liver
News
Contact
Choose Region
China
US
International
Linkedin
Search for:
News & press releases
News & press releases
monimono
2017-12-05T08:33:16+00:00
August 31, 2018
Exalenz Announces Second Quarter 2018 Financial Results
Read more
July 10, 2018
Exalenz Bioscience’s Non-Invasive BreathID® Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH
Read more
June 18, 2018
Exalenz Announces Confidential Submission of Draft Registration Statement for Initial Public Offering
Read more
April 30, 2018
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer
Read more
March 13, 2018
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients
Read more
March 12, 2018
Exalenz Announces Fourth Quarter and Full Year 2017 Financial Results
Read more
March 9, 2018
Exalenz Bioscience to Participate in Upcoming Investor Conferences
Read more
January 23, 2018
Exalenz Bioscience announces positive clinical trial results for the diagnosis of clinically significant portal hypertension in NASH patients
Read more
April 17, 2017
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
Read more
Nov 1, 2016
Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States
Read more
You have reached the US website
click here
for the international website.
×
